Topic: Metabolic Signaling and Therapy Resistance
Guest Editor(s)
Special Issue Introduction
Metabolic reprogramming is emerging as a crucial phenomenon in the adaptive stress response of cancer cells, playing a pivotal role in mediating cancer resistance to therapy and adaptation. These metabolic changes may happen very early after drug treatment and may produce signaling molecules.
For example, our recent research has shown that perturbation following pemetrexed treatment of mesothelioma cells may impinge on the onset of the SASP-driven secretome rearrangement. Additionally, metabolites have the potential to act as fast-acting signaling molecules, functioning in a paracrine way. Under stressful conditions, specific patterns of metabolite emerge at the intracellular and extracellular levels and provide key signaling within the tumor microenvironment.
The intrinsic and extrinsic metabolic cell rewiring during metastasis has also garnered significant attention as a research focus and the relevance of the premetastatic niche conditioning from a metabolic point of view is increasing, spanning across both solid and non-solid tumor contexts.
Moreover, the metabolic determinants of circulating tumor cells are also gaining recent attention, given the possibility for those latter cell subpopulations to mediate therapy resistance.
We invite our esteemed colleagues for an interdisciplinary discourse that encompasses proteomics, genomics, metabolomics and epigenomics, the key emerging aspects of metabolic modulation of therapy resistance and to suggest and show possible clinically relevant approaches of translational relevance.
Proposed topics include, but are not limited to:
1. Oncometabolite signaling；
2. Tumor microenvironment signaling；
3. Arachidonic acid signaling；
4. Metabolic reprogramming and chemoresistance；
5. Circulating tumor cells;
6. Metabolic changes in metastasis;
7. Abating lipid-mediated resistance to therapy;
8. Cancer stem cells and metabolic reprogramming during stress;
etc.
For example, our recent research has shown that perturbation following pemetrexed treatment of mesothelioma cells may impinge on the onset of the SASP-driven secretome rearrangement. Additionally, metabolites have the potential to act as fast-acting signaling molecules, functioning in a paracrine way. Under stressful conditions, specific patterns of metabolite emerge at the intracellular and extracellular levels and provide key signaling within the tumor microenvironment.
The intrinsic and extrinsic metabolic cell rewiring during metastasis has also garnered significant attention as a research focus and the relevance of the premetastatic niche conditioning from a metabolic point of view is increasing, spanning across both solid and non-solid tumor contexts.
Moreover, the metabolic determinants of circulating tumor cells are also gaining recent attention, given the possibility for those latter cell subpopulations to mediate therapy resistance.
We invite our esteemed colleagues for an interdisciplinary discourse that encompasses proteomics, genomics, metabolomics and epigenomics, the key emerging aspects of metabolic modulation of therapy resistance and to suggest and show possible clinically relevant approaches of translational relevance.
Proposed topics include, but are not limited to:
1. Oncometabolite signaling；
2. Tumor microenvironment signaling；
3. Arachidonic acid signaling；
4. Metabolic reprogramming and chemoresistance；
5. Circulating tumor cells;
6. Metabolic changes in metastasis;
7. Abating lipid-mediated resistance to therapy;
8. Cancer stem cells and metabolic reprogramming during stress;
etc.
Keywords
Metabolic signaling, therapy resistance, oncometabolite, tumor microenvironment, stress adaptation, cancer stem cells, lipid mediators, CTCs, metastasis
Submission Deadline
31 Jul 2024
Submission Information
For Author Instructions, please refer to https://www.oaepublish.com/cdr/author_instructions
For Online Submission, please login at https://oaemesas.com/login?JournalId=cdr&SpecialIssueId=CDR230831
Submission Deadline: 31 Jul 2024
Contacts: Susan Song, Managing Editor, Susan@cdrjournal.com
